Please use this identifier to cite or link to this item:
Title: Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients
Author: Camprubí, Daniel
Almuedo Riera, Alex
Martí Soler, Helena
Soriano Viladomiu, Alex
Hurtado, Juan Carlos
Subirà, Carme
Grau Pujol, Berta
Krolewiecki, Alejandro J.
Muñoz Gutiérrez, José
Keywords: COVID-19
Issue Date: 11-Nov-2020
Publisher: Public Library of Science (PLoS)
Abstract: Ivermectin has recently shown efficacy against SARS-CoV-2 in-vitro. We retrospectively reviewed severe COVID-19 patients receiving standard doses of ivermectin and we compared clinical and microbiological outcomes with a similar group of patients not receiving ivermectin. No differences were found between groups. We recommend the evaluation of high-doses of ivermectin in randomized trials against SARS-CoV-2.
Note: Reproducció del document publicat a:
It is part of: PLoS One, 2020, vol. 15, num. 11, p. e0242184
Related resource:
ISSN: 1932-6203
Appears in Collections:Articles publicats en revistes (ISGlobal)
Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
710488.pdf364.87 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons